Open Payments

CPMC-R.K. DAVIES MEDICAL CENTER

Type
Teaching hospital
Where
SAN FRANCISCO, CA
Medicare CCN
050008
Received
$1,407,669 in 178 records, 2025 ($78,409 general, $1,329,260 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment15$78,409
2025Research payment163$1,329,260

By company

CompanyRecordsAmountYears
Alnylam Pharmaceuticals Inc.59$293,8942025
Edwards Lifesciences Corporation25$272,4502025
Abbott Laboratories13$135,8672025
Boston Scientific Corporation6$126,1172025
Eli Lilly and Company4$118,2332025
GENZYME CORPORATION4$99,7692025
Gilead Sciences, Inc.11$70,1732025
Stryker Corporation13$42,4892025
Iovance Biotherapeutics, Inc.1$38,9802025
ModernaTX, Inc.6$37,9722025
E.R. Squibb & Sons, L.L.C.4$29,5852025
Jenavalve Technology, Inc.1$27,6252025
Celgene Corporation2$25,6252025
Enterra Medical, Inc.4$20,3952025
UCB SA1$19,9812025
Genentech, Inc.1$14,3042025
GT Medical Technologies, Inc19$12,9462025
Biogen, Inc.2$11,6712025
KARL STORZ Endoscopy-America1$8,7082025
Carl Zeiss Meditec USA, Inc.1$8772025

By nature of payment

NatureRecordsAmount
Research payment163$1,329,260
Long term medical supply or device loan13$49,906
Compensation for services other than consulting, including serving as faculty or as a speaker at a v1$27,625
Food and Beverage1$877

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Stryker Corporation$5,360Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$5,360Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$5,360Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$3,808Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$3,716Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$3,477Long term medical supply or device loanIn-kind items and servicesCORE Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$3,477Long term medical supply or device loanIn-kind items and servicesCORE Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$3,000Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$3,000Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$3,000Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$1,596Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$41Long term medical supply or device loanIn-kind items and servicesPROCUITY Device, PATIENT HANDLING - PH2025
2025-12-19Edwards Lifesciences Corporation$1,937Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2025
2025-12-18Carl Zeiss Meditec USA, Inc.$877Food and BeverageIn-kind items and servicesRetina Workplace Device, Software2025
2025-12-16Boston Scientific Corporation$2,599Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN_ICSIMPLAAFY2025
2025-12-11Edwards Lifesciences Corporation$7,511Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072025
2025-12-10Edwards Lifesciences Corporation$25,304Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2025
2025-12-09Boston Scientific Corporation$3,851Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMADVENT PAS2025
2025-12-08Alnylam Pharmaceuticals Inc.$103Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-12-05Edwards Lifesciences Corporation$44,420Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2025
2025-12-03Alnylam Pharmaceuticals Inc.$1,733Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-12-03Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-12-03Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-12-03Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-12-03Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-12-03Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-12-03Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-11-30Enterra Medical, Inc.$283Research paymentCash or cash equivalentNavigate2025
2025-11-28Edwards Lifesciences Corporation$2,474Research paymentCash or cash equivalentCLASP IID 2018-072025
2025-11-21E.R. Squibb & Sons, L.L.C.$17,048Research paymentCash or cash equivalentA Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy 2025
2025-11-19Alnylam Pharmaceuticals Inc.$16,072Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-11-19Alnylam Pharmaceuticals Inc.$12,249Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-11-19Alnylam Pharmaceuticals Inc.$2,869Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-11-19Alnylam Pharmaceuticals Inc.$1,733Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-11-19Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-11-19Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-11-18Boston Scientific Corporation$30,311Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMADVENT PAS2025
2025-11-05Abbott Laboratories$11,208Research paymentCash or cash equivalent Device, Structural HeartNCT03904147--TRILUMINATE Pivotal Trial2025
2025-11-04Boston Scientific Corporation$32,492Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMADVENT LTO2025
2025-11-03Abbott Laboratories$30,282Research paymentCash or cash equivalent Device, Structural HeartNCT06223789--VOLT-AF IDE Clinical Study2025
2025-11-03Gilead Sciences, Inc.$2,624Research paymentCash or cash equivalentLivdelzi Drug, INFLAMA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien2025
2025-10-31Enterra Medical, Inc.$2,250Research paymentCash or cash equivalentNavigate2025
2025-10-30Abbott Laboratories$1,340Research paymentCash or cash equivalent Device, Structural HeartNCT06223789--VOLT-AF IDE Clinical Study2025
2025-10-28Boston Scientific Corporation$55,539Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMADVENT PAS2025
2025-10-28Gilead Sciences, Inc.$3,301Research paymentCash or cash equivalentLivdelzi Drug, INFLAMAn Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho2025
2025-10-24ModernaTX, Inc.$11,955Research paymentCash or cash equivalentAn Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants2025
2025-10-22Celgene Corporation$23,750Research paymentCash or cash equivalentA Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy 2025
2025-10-16Alnylam Pharmaceuticals Inc.$16,072Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$15,271Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$15,271Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$15,271Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$13,638Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$13,638Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$13,638Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$12,249Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$12,249Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$2,869Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$2,869Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$1,770Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Edwards Lifesciences Corporation$1,579Research paymentCash or cash equivalentALLIANCE 2021-052025
2025-10-16Edwards Lifesciences Corporation$1,548Research paymentCash or cash equivalentPartner3 2015-082025
2025-10-16Edwards Lifesciences Corporation$1,080Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2025
2025-10-16Alnylam Pharmaceuticals Inc.$726Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$726Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$726Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Edwards Lifesciences Corporation$540Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2025
2025-10-16Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-16Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-10-15Edwards Lifesciences Corporation$607Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2025
2025-10-09Edwards Lifesciences Corporation$176Research paymentCash or cash equivalentThe PROGRESS Trial 2021-012025
2025-10-02Edwards Lifesciences Corporation$17,382Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2025
2025-10-01Enterra Medical, Inc.$17,250Research paymentCash or cash equivalentNavigate2025
2025-10-01Edwards Lifesciences Corporation$7,133Research paymentCash or cash equivalentPartner3 2015-082025
2025-10-01Gilead Sciences, Inc.$1,250Research paymentCash or cash equivalentLivdelzi Drug, INFLAMA 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o2025
2025-10-01Gilead Sciences, Inc.$1,165Research paymentCash or cash equivalentLivdelzi Drug, INFLAMA 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o2025
2025-10-01Edwards Lifesciences Corporation$405Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072025
2025-09-30Edwards Lifesciences Corporation$41,022Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072025
2025-09-30Enterra Medical, Inc.$611Research paymentCash or cash equivalentNavigate2025
2025-09-23Gilead Sciences, Inc.$1,310Research paymentCash or cash equivalentLivdelzi Drug, INFLAMA 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o2025
2025-09-18Iovance Biotherapeutics, Inc.$38,980Research paymentCash or cash equivalentAmtagvi Drug, OncologyNCT023605792025
2025-09-18Edwards Lifesciences Corporation$8,189Research paymentCash or cash equivalentALLIANCE 2021-052025
2025-09-16Jenavalve Technology, Inc.$27,625Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-09-12Gilead Sciences, Inc.$11,645Research paymentCash or cash equivalentLivdelzi Drug, INFLAMA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien2025
2025-09-03Alnylam Pharmaceuticals Inc.$10,000Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-09-03Alnylam Pharmaceuticals Inc.$2,540Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-08-21Edwards Lifesciences Corporation$1,946Research paymentCash or cash equivalentPartner3 2015-082025
2025-08-19Gilead Sciences, Inc.$7,903Research paymentCash or cash equivalentLivdelzi Drug, INFLAMA 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o2025
2025-08-15Alnylam Pharmaceuticals Inc.$206Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-08-15Alnylam Pharmaceuticals Inc.$103Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-08-13Alnylam Pharmaceuticals Inc.$3,800Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-08-13Abbott Laboratories$2,121Research paymentCash or cash equivalent Device, Structural HeartNCT03904147--TRILUMINATE Pivotal Trial2025
2025-08-13Abbott Laboratories$2,092Research paymentCash or cash equivalent Device, Structural HeartNCT06223789--VOLT-AF IDE Clinical Study2025
2025-08-13Alnylam Pharmaceuticals Inc.$1,538Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-08-13Alnylam Pharmaceuticals Inc.$1,500Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-08-13GT Medical Technologies, Inc$985Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$985Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$729Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$729Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$729Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$729Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$729Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$729Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$729Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$729Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$729Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$729Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$627Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$627Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$499Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$499Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$499Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$465Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-13GT Medical Technologies, Inc$465Research paymentCash or cash equivalentGammaTile Device, CNSGTM-1012025
2025-08-11GENZYME CORPORATION$39,040Research paymentCash or cash equivalentA Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa2025
2025-08-01ModernaTX, Inc.$16,080Research paymentCash or cash equivalentAn Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants2025
2025-08-01Alnylam Pharmaceuticals Inc.$4,579Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-08-01Alnylam Pharmaceuticals Inc.$236Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-08-01Alnylam Pharmaceuticals Inc.$206Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-08-01Alnylam Pharmaceuticals Inc.$93Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-07-31Edwards Lifesciences Corporation$34,344Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2025
2025-07-31Abbott Laboratories$2,810Research paymentCash or cash equivalent Device, Structural HeartNCT06223789--VOLT-AF IDE Clinical Study2025
2025-07-23Alnylam Pharmaceuticals Inc.$13,638Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-07-22Gilead Sciences, Inc.$26,670Research paymentCash or cash equivalentLivdelzi Drug, INFLAMA 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o2025
2025-07-22Edwards Lifesciences Corporation$4,413Research paymentCash or cash equivalentThe PROGRESS Trial 2021-012025
2025-07-15Gilead Sciences, Inc.$3,630Research paymentCash or cash equivalentLivdelzi Drug, INFLAMAn Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho2025
2025-07-02Alnylam Pharmaceuticals Inc.$12,249Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-07-02Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-06-26Edwards Lifesciences Corporation$25,203Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2025
2025-06-23Alnylam Pharmaceuticals Inc.$2,869Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-06-23Alnylam Pharmaceuticals Inc.$726Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-06-23Alnylam Pharmaceuticals Inc.$436Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-06-02UCB SA$19,981Research paymentCash or cash equivalentZilbrysq Biological, NeurologyPhase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis2025
2025-05-28Celgene Corporation$1,875Research paymentCash or cash equivalentConnect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Regist2025
2025-05-27Boston Scientific Corporation$1,324Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN_ICOPTION2025
2025-05-12Abbott Laboratories$5,760Research paymentCash or cash equivalent Device, Structural HeartNCT03904147--TRILUMINATE Pivotal Trial2025
2025-05-06Gilead Sciences, Inc.$9,574Research paymentCash or cash equivalentLivdelzi Drug, INFLAMAn Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho2025
2025-05-02Alnylam Pharmaceuticals Inc.$15,271Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-05-02Alnylam Pharmaceuticals Inc.$13,638Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-05-02Alnylam Pharmaceuticals Inc.$13,638Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-05-02ModernaTX, Inc.$4,295Research paymentCash or cash equivalentAn Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants2025
2025-05-02Alnylam Pharmaceuticals Inc.$2,869Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-05-02Alnylam Pharmaceuticals Inc.$726Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-04-23Abbott Laboratories$12,787Research paymentCash or cash equivalent Device, Structural HeartNCT06223789--VOLT-AF IDE Clinical Study2025
2025-04-23ModernaTX, Inc.$729Research paymentCash or cash equivalentAn Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants2025
2025-04-14Genentech, Inc.$14,304Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2025
2025-04-11Stryker Corporation$1,291Research paymentCash or cash equivalentTHE CITADEL EMBOLIZATION DEVICE FEASIBILITY STUDY2025
2025-04-11ModernaTX, Inc.$1,000Research paymentCash or cash equivalentAn Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants2025
2025-04-10KARL STORZ Endoscopy-America$8,708Long term medical supply or device loanIn-kind items and servicesn.a. Device, OR12025
2025-04-08Eli Lilly and Company$4,812Research paymentCash or cash equivalentA STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2025
2025-04-03Edwards Lifesciences Corporation$7,251Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2025
2025-04-03Edwards Lifesciences Corporation$5,974Research paymentCash or cash equivalentALLIANCE 2021-052025
2025-04-03Edwards Lifesciences Corporation$3,205Research paymentCash or cash equivalentPartner3 2015-082025
2025-04-02Alnylam Pharmaceuticals Inc.$13,638Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-04-02Alnylam Pharmaceuticals Inc.$1,113Research paymentCash or cash equivalentA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2025
2025-04-01Abbott Laboratories$2,720Research paymentCash or cash equivalent Device, Structural HeartNCT06223789--VOLT-AF IDE Clinical Study2025
2025-04-01Abbott Laboratories$2,720Research paymentCash or cash equivalent Device, Structural HeartNCT06223789--VOLT-AF IDE Clinical Study2025
2025-03-20Gilead Sciences, Inc.$1,100Research paymentCash or cash equivalentLivdelzi Drug, INFLAMAn Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho2025
2025-03-19Edwards Lifesciences Corporation$3,415Research paymentCash or cash equivalentSM3 Trial 2017-032025
2025-03-17Abbott Laboratories$3,014Research paymentCash or cash equivalent Device, Structural HeartNCT03904147--TRILUMINATE Pivotal Trial2025
2025-02-26Abbott Laboratories$28,760Research paymentCash or cash equivalent Device, Structural HeartNCT06223789--VOLT-AF IDE Clinical Study2025
2025-02-24GENZYME CORPORATION$30,271Research paymentCash or cash equivalentA Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa2025
2025-02-24GENZYME CORPORATION$16,781Research paymentCash or cash equivalentA Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa2025
2025-02-24GENZYME CORPORATION$13,676Research paymentCash or cash equivalentA Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa2025
2025-02-21Abbott Laboratories$30,250Research paymentCash or cash equivalentFREESTYLE LIBRE 2 Device, Diabetes CareNCT06999356 --- Salud Diabetes: A Pilot Study Comparing Lifestyle Interventions and Real-Time Continuous Glucose Monitor2025
2025-02-21Biogen, Inc.$3,000Research paymentCash or cash equivalentADUHELM Biological, NeurologyA Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Bene2025
2025-02-11Eli Lilly and Company$105,655Research paymentCash or cash equivalentAMYVID Drug, NeuroscienceA STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC2025
2025-02-11E.R. Squibb & Sons, L.L.C.$495Research paymentCash or cash equivalentOPDIVO Biological, OncologyA Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carc2025
2025-01-27Eli Lilly and Company$7,204Research paymentIn-kind items and servicesA STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC2025
2025-01-22ModernaTX, Inc.$3,912Research paymentCash or cash equivalentAn Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants2025
2025-01-21E.R. Squibb & Sons, L.L.C.$1,458Research paymentCash or cash equivalentOPDIVO Biological, OncologyA Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resecti2025
2025-01-20Edwards Lifesciences Corporation$25,384Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2025
2025-01-17E.R. Squibb & Sons, L.L.C.$10,584Research paymentCash or cash equivalentOPDUALAG Drug, OncologyA Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab andNivolumab Fixed-dose Combination 2025
2025-01-09Eli Lilly and Company$561Research paymentIn-kind items and servicesA STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2025
2025-01-08Biogen, Inc.$8,671Research paymentCash or cash equivalentQALSODY Drug, ALSA Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismuta2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Francisco CountySan Francisco city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.

MeasurePlace (city or town)
San Francisco, CA
County
San Francisco County, CA
State
California
Population B01003830,235830,23539,287,377
Population, 2020 census P1873,965873,96539,538,223
Median age B0100240.040.037.9
Under 18 B0100113.7%13.7%22.0%
65 and over B0100117.6%17.6%15.7%
Households B11001363,970363,97013,548,091
Foreign born B0500234.0%34.0%27.0%
Median household income B19013$140,970$140,970$99,122
Median family income B19113$171,141$171,141$113,346
Per capita income B19301$92,289$92,289$49,513
Poverty rate B1700111.2%11.2%12.0%
Unemployment rate B230256.1%6.1%6.6%
Civilian labor force B23025507,262507,26220,068,466
Mean commute (minutes) B0801330.430.428.7
Bachelor's degree or higher B1500360.3%60.3%37.1%
Housing units B25001414,602414,60214,644,735
Owner-occupied B2500338.2%38.2%55.9%
Renters B2500361.8%61.8%44.1%
Median home value B25077$1,394,500$1,394,500$734,700
Median gross rent B25064$2,476$2,476$2,036
White, not Hispanic B0300236.8%36.8%33.8%
Black B030024.7%4.7%5.2%
Hispanic or Latino B0300216.2%16.2%40.2%
Asian B0300234.9%34.9%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.